

Ronald Vender

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11596344/publications.pdf>

Version: 2024-02-01

8
papers

860
citations

1163117
8
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

1139
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 141-150.	1.2	267
2	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 60-69.e9.	1.2	258
3	Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. <i>Lancet, The</i> , 2021, 397, 475-486.	13.7	136
4	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blind trial. <i>British Journal of Dermatology</i> , 2020, 182, 1348-1358.	1.5	117
5	Review of Systemic Treatment Options for Adult Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 31-39.	1.2	42
6	A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 78-83.	1.2	17
7	Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies. <i>Dermatology and Therapy</i> , 2018, 8, 17-32.	3.0	14
8	Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 2S-40S.	1.2	9